Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alentis Therapeutics
Biotech
CSL pays $355M to co-develop Alentis’ ph. 2-stage fibrosis drug
Australia’s CSL is paying $355 million upfront for the rights to Alentis Therapeutics’ phase 2-stage fibrosis drug.
James Waldron
Oct 5, 2026 4:14am
Cabaletta corrals cell therapy Legend—Chutes & Ladders
Oct 17, 2025 8:30am
Fierce Biotech's 2025 Fierce 15
Sep 22, 2025 8:00am
Is Basel the next Boston? The Swiss biotech hub raising its game
Aug 8, 2025 9:50am
Catalio bankrolls biotechs with $400M-plus fund
Jul 1, 2025 4:12pm
Alentis raises $181M series D to bring ADCs to the clinic
Nov 12, 2024 7:00am
